155 related articles for article (PubMed ID: 2757963)
1. Interferon alpha-2b as treatment for Philadelphia-negative chronic myeloproliferative disorders with excessive thrombocytosis.
Lazzarino M; Vitale A; Morra E; Gagliardi A; Bernasconi P; Torromeo C; Inverardi D; Burgio V; Castello A; Bernasconi C
Br J Haematol; 1989 Jun; 72(2):173-7. PubMed ID: 2757963
[TBL] [Abstract][Full Text] [Related]
2. Interferon-alpha-induced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis.
Chott A; Gisslinger H; Thiele J; Fritz E; Linkesch W; Radaszkiewicz T; Ludwig H
Br J Haematol; 1990 Jan; 74(1):10-6. PubMed ID: 2310690
[TBL] [Abstract][Full Text] [Related]
3. [Therapy of thrombocytosis in myeloproliferative syndromes using recombinant interferon-alpha-2a].
Tichelli A; Gratwohl A; Delacrétaz F; Dazzi H; Stebler C; Wernli M; Holdener EE; Nissen C; Speck B
Schweiz Med Wochenschr; 1989 Sep; 119(39):1347-52. PubMed ID: 2799342
[TBL] [Abstract][Full Text] [Related]
4. alpha Interferon treatment of essential thrombocythaemia and other myeloproliferative disorders with excessive thrombocytosis.
Yataganas X; Meletis J; Plata E; Viniou N; Deligiannis F; Tsekoura C; Voscaridou E; Boussiotis V; Rombos J; Vayopoulos G
Eur J Cancer; 1991; 27 Suppl 4():S69-71. PubMed ID: 1799484
[TBL] [Abstract][Full Text] [Related]
5. Treatment of thrombocytosis in myeloproliferative disorders with interferon alpha-2a.
Tichelli A; Gratwohl A; Berger C; Lori A; Würsch A; Dieterle A; Thomssen C; Nissen C; Holdener E; Speck B
Blut; 1989 Jan; 58(1):15-9. PubMed ID: 2644994
[TBL] [Abstract][Full Text] [Related]
6. [Alfa-2b interferon in the treatment of thrombocytosis associated to chronic non leukemic myeloproliferative syndromes].
Petit J; Callís M; Domingo Albós A; Fernández de Sevilla A; Besses C; Martí JM
Med Clin (Barc); 1993 Nov; 101(16):601-3. PubMed ID: 8271861
[TBL] [Abstract][Full Text] [Related]
7. Treatment of thrombocytosis in chronic myeloproliferative disorders with interferon alfa-2b.
Seewann HL; Zikulnig R; Gallhofer G; Schmid C
Eur J Cancer; 1991; 27 Suppl 4():S58-62; discussion S62-3. PubMed ID: 1799482
[TBL] [Abstract][Full Text] [Related]
8. Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis.
Talpaz M; Kurzrock R; Kantarjian H; O'Brien S; Gutterman JU
Am J Med; 1989 May; 86(5):554-8. PubMed ID: 2712063
[TBL] [Abstract][Full Text] [Related]
9. Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders.
Ludwig H; Linkesch W; Gisslinger H; Fritz E; Sinzinger H; Radaszkiewicz T; Chott A; Flener R; Micksche M
Cancer Immunol Immunother; 1987; 25(3):266-73. PubMed ID: 3677127
[TBL] [Abstract][Full Text] [Related]
10. Interferon alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration.
Alimena G; Morra E; Lazzarino M; Liberati AM; Montefusco E; Inverardi D; Bernasconi P; Mancini M; Donti E; Grignani F
Blood; 1988 Aug; 72(2):642-7. PubMed ID: 3165298
[TBL] [Abstract][Full Text] [Related]
11. Long-term interferon therapy for thrombocytosis in myeloproliferative diseases.
Gisslinger H; Ludwig H; Linkesch W; Chott A; Fritz E; Radaszkiewicz T
Lancet; 1989 Mar; 1(8639):634-7. PubMed ID: 2564458
[TBL] [Abstract][Full Text] [Related]
12. The role of alpha-interferon in essential thrombocythaemia, polycythaemia vera and myelofibrosis with myeloid metaplasia (MMM): a concise update.
Sacchi S
Leuk Lymphoma; 1995 Sep; 19(1-2):13-20. PubMed ID: 8574158
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies.
Freund M; von Wussow P; Diedrich H; Eisert R; Link H; Wilke H; Buchholz F; LeBlanc S; Fonatsch C; Deicher H
Br J Haematol; 1989 Jul; 72(3):350-6. PubMed ID: 2765403
[TBL] [Abstract][Full Text] [Related]
14. Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy.
Gilbert HS
Cancer; 1998 Sep; 83(6):1205-13. PubMed ID: 9740087
[TBL] [Abstract][Full Text] [Related]
15. Acute myelofibrosis: response to recombinant human interferon alpha-2a.
List AF; Kummet TD; Kerr DM
Leuk Res; 1990; 14(4):321-6. PubMed ID: 2332985
[TBL] [Abstract][Full Text] [Related]
16. Interferon alpha-2a to control thrombocytosis in chronic myelogenous leukemia and essential thrombocythemia.
Jootar S
Asian Pac J Allergy Immunol; 1989 Dec; 7(2):103-5. PubMed ID: 2624663
[TBL] [Abstract][Full Text] [Related]
17. Interferon Alpha Has a Strong Anti-tumor Effect in Philadelphia-negative Myeloproliferative Neoplasms.
Mondello P; Di Mirto C; Cuzzocrea S; Arrigo C; Mian M; Pitini V
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e489-e495. PubMed ID: 31231012
[TBL] [Abstract][Full Text] [Related]
18. Histomorphometry of bone marrow biopsies in chronic myeloproliferative disorders with associated thrombocytosis--features of significance for the diagnosis of primary (essential) thrombocythaemia.
Thiele J; Schneider G; Hoeppner B; Wienhold S; Zankovich R; Fischer R
Virchows Arch A Pathol Anat Histopathol; 1988; 413(5):407-17. PubMed ID: 3140482
[TBL] [Abstract][Full Text] [Related]
19. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.
Gowin K; Jain T; Kosiorek H; Tibes R; Camoriano J; Palmer J; Mesa R
Leuk Res; 2017 Mar; 54():73-77. PubMed ID: 28113109
[TBL] [Abstract][Full Text] [Related]
20. Interferon alfa-2b therapy in untreated early stage, B-chronic lymphocytic leukaemia patients: one-year follow-up.
Boussiotis VA; Pangalis GA
Br J Haematol; 1991 Oct; 79 Suppl 1():30-3. PubMed ID: 1931705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
